Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach

被引：22

作者：

Sarkadi, Balazs ^{[1
]}

Saskoi, Eva ^{[2
]}

Butz, Henriett ^{[1
,2
,3
]}

Patocs, Attila ^{[1
,2
,3
]}

机构：

[1] ELKH Hereditary Canc Res Grp, H-1052 Budapest, Hungary

[2] Natl Inst Oncol, Dept Mol Genet, H-1122 Budapest, Hungary

[3] Semmelweis Univ, Dept Lab Med, H-1085 Budapest, Hungary

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 03期

关键词：

pheochromocytoma; paraganglioma; hereditary tumor; susceptibility genes; germline; somatic; metastatic; treatment; personalized medicine; RECEPTOR RADIONUCLIDE THERAPY; FUNCTIONAL IMAGING MODALITIES; GERMLINE MUTATIONS; METASTATIC PHEOCHROMOCYTOMA; SPORADIC PHEOCHROMOCYTOMAS; RET PROTOONCOGENE; HIF2A MUTATIONS; MAX MUTATIONS; EXPRESSION; ACTIVATION;

D O I：

10.3390/ijms23031450

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pheochromocytomas and paragangliomas are the most heritable endocrine tumors. In addition to the inherited mutation other driver mutations have also been identified in tumor tissues. All these genetic alterations are clustered in distinct groups which determine the pathomechanisms. Most of these tumors are benign and their surgical removal will resolve patient management. However, 5-15% of them are malignant and therapeutical possibilities for them are limited. This review provides a brief insight about the tumorigenesis associated with pheochromocytomas/paragangliomas in order to present them as potential therapeutical targets.

引用

页数：17

共 50 条

[31] Differential diagnosis of pheochromocytomas and paragangliomas
Anne Marie McNicol
Endocrine Pathology, 2001, 12 : 407 - 415
[32] Differential diagnosis of pheochromocytomas and paragangliomas
McNicol, AM
ENDOCRINE PATHOLOGY, 2001, 12 (04) : 407 - 415
[33] Molecular Imaging of Paragangliomas and Pheochromocytomas
Burkett, Brian J.
Johnson, Derek R.
RADIOLOGY-IMAGING CANCER, 2025, 7 (01):
[34] Sunitinib Targets in Pheochromocytomas and Paragangliomas
Cassol, C.
Winer, D.
Liu, W.
Guo, M.
Asa, S.
MODERN PATHOLOGY, 2013, 26 : 130A - 130A
[35] Sunitinib Targets in Pheochromocytomas and Paragangliomas
Cassol, C.
Winer, D.
Liu, W.
Guo, M.
Asa, S.
LABORATORY INVESTIGATION, 2013, 93 : 130A - 130A
[36] Molecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, Svetlana O.
Snezhkina, Anastasiya V.
Zaretsky, Andrew R.
Alekseev, Boris Y.
Pokrovsky, Anatoly V.
Golovyuk, Alexander L.
Melnikova, Nataliya V.
Stepanov, Oleg A.
Kalinin, Dmitry V.
Moskalev, Alexey A.
Krasnov, George S.
Dmitriev, Alexey A.
Kudryavtseva, Anna V.
ONCOTARGET, 2017, 8 (15) : 25756 - 25782
[37] Management and treatment of pheochromocytomas and paragangliomas
Mannelli, Massimo
PHEOCHROMOCYTOMA, 2006, 1073 : 405 - 416
[38] Pheochromocytomas and paragangliomas in humans and dogs
Galac, S.
Korpershoek, E.
VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (04) : 1158 - 1170
[39] Perioperative management of paragangliomas and pheochromocytomas
Fermandois, Magdalena
Altamirano, Jaime
Rojas, Felipe
Roman, Cristobal
Pinto, Ivan
MEDWAVE, 2020, 20 (02):
[40] DIAGNOSIS Imaging of pheochromocytomas and paragangliomas
Chew, Shern L.
NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (04) : 193 - 194

← 1 2 3 4 5 →